SCHEMBL2710330

SCHEMBL2710330

COc1cc(F)c(-c2c3ccccc3c(-c3c(F)cc(OC)cc3F)c3c(F)cccc23)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 2/20 0.38
ALDH1A1 P00352 2/20 0.37
MIF P14174 1/20 0.36
KDM1A O60341 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 3/20 0.34
CYP1A1 P04798 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1B1 Q16678 2/20 0.34
CYP2E1 P05181 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2A6 P11509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2709778 0.94 NFE2L2 (0.35) NFE2L2ALDH1A1MIFKDM1AMAOA
SCHEMBL2725925 0.93 NFE2L2 (0.34) NFE2L2ALDH1A1MIFKDM1AMAOA
SCHEMBL2711752 0.91 CYP1A2 (0.42) NFE2L2ALDH1A1KDM1AMAOAMAOB
SCHEMBL12086196 0.91 CYP1A2 (0.42) NFE2L2ALDH1A1KDM1AMAOAMAOB
SCHEMBL2727335 0.90 ALDH1A1 (0.37) NFE2L2ALDH1A1MIFKDM1AMAOA
SCHEMBL2710065 0.90 NFE2L2 (0.33) NFE2L2ALDH1A1MIFKDM1AMAOA
SCHEMBL2712835 0.90 ACHE (0.45) NFE2L2ALDH1A1MAOBRAB9ANPC1
SCHEMBL12086197 0.90 ACHE (0.42) NFE2L2ALDH1A1MAOBRAB9ANPC1
SCHEMBL2711671 0.89 L3MBTL1 (0.34) NFE2L2ALDH1A1MIFKDM1AMAOA
SCHEMBL2724899 0.88 TAAR1 (0.38) NFE2L2ALDH1A1KDM1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
EP-2445987-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS Cyalume Technologies, Inc (US) 2012-05-02 EP disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
WO-2010151654-A1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECHNOLOGIES, INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 NFE2L2 346/4885ALDH1A1 34/4885MIF 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.